COVID-19 CoronaVac in Patients With Autoimmune Rheumatic Diseases and HIV/AIDS (CoronavRheum)
Immunogenicity and Safety of the CoronaVac Vacccine in Patients With Autoimmune Rheumatic Diseases and People Living With HIV/AIDS
Sponsor: University of Sao Paulo General Hospital
A PHASE4 clinical study on AIDS and COVID-19, this trial is completed. The trial is conducted by University of Sao Paulo General Hospital and has accumulated 11 data snapshots since 2021. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Apr 2024 — Jul 2024 [monthly]
Completed PHASE4
Status: Active Not Recruiting → Completed
-
Dec 2023 — Apr 2024 [monthly]
Active Not Recruiting PHASE4
-
Jun 2022 — Dec 2023 [monthly]
Active Not Recruiting PHASE4
▶ Show 6 earlier versions
-
Nov 2021 — Jun 2022 [monthly]
Active Not Recruiting PHASE4
-
Oct 2021 — Nov 2021 [monthly]
Active Not Recruiting PHASE4
-
Sep 2021 — Oct 2021 [monthly]
Active Not Recruiting PHASE4
Status: Recruiting → Active Not Recruiting
-
Jun 2021 — Sep 2021 [monthly]
Recruiting PHASE4
-
Apr 2021 — Jun 2021 [monthly]
Recruiting PHASE4
Phase: NA → PHASE4
-
Mar 2021 — Apr 2021 [monthly]
Recruiting NA
First recorded
Feb 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- University of Sao Paulo General Hospital
For direct contact, visit the study record on ClinicalTrials.gov .